Table 4.

Results from emulsion stability analyses when drug was mixed with Numeta G13E + (average ± SD; n = 3)

Drug		Mix ratio	Z-average (nm)	PDI	%PFAT5		pH
					0 h	4 h	0 h	4 h
Numeta G13E +		Control	248 ± 2	0.13 ± 0.02	0.23	0.12	5.80 ± 0.07	5.79 ± 0.05
Two-component analysis (drug + PN)	Morphine + Numeta G13E +	1 + 1	249 ± 1	0.13 ± 0.02	0.19 ± 0.03	0.19 ± 0.01a	5.92 ± 0.01	5.90 ± 0.01
		1 + 7	249 ± 2	0.13 ± 0.01	0.29 ± 0.05	0.20 ± 0.05	5.81 ± 0.02	5.84 ± 0.03
		1 + 39	247 ± 2	0.15 ± 0.03	0.31 ± 0.08	0.25 ± 0.05	5.79 ± 0.01	5.79 ± 0.01
	Cefotaxime + Numeta G13E +	1 + 1	252 ± 2	0.13 ± 0.02	0.28 ± 0.04	0.41 ± 0.05*	5.71 ± 0.01	5.66 ± 0.02
		9 + 1	248 ± 2	0.14 ± 0.03	0.24 ± 0.09	0.15 ± 0.15	5.84 ± 0.01	5.86 ± 0.01
		1 + 20	249 ± 2	0.12 ± 0.01	0.39 ± 0.04	0.24 ± 0.02	5.84 ± 0.02	5.83 ± 0.02
	Dopamine + Numeta G13E +	1 + 1	248 ± 1	0.13 ± 0.02	0.24 ± 0.03	0.23 ± 0.05	5.86 ± 0.01	5.89 ± 0.01
		1 + 6	247 ± 2	0.15 ± 0.02	0.25 ± 0.02	0.22 ± 0.03	5.67 ± 0.01	5.66 ± 0.03
		1 + 56	248 ± 2	0.13 ± 0.02	0.42 ± 0.09*	0.46 ± 0.06*	5.81 ± 0.02	5.83 ± 0.03
Three-component analysis (drug + morphine + PN)	Dopamine + morphine + Numeta G13E +	1 + 1 + 1	248 ± 2	0.14 ± 0.02	0.05 ± 0.01	0.16 ± 0.03	5.90 ± 0.01	5.87 ± 0.01
		1 + 1 + 10	248 ± 3	0.13 ± 0.02	0.07 ± 0.01	0.16 ± 0.01	5.81 ± 0.01	5.81 ± 0.01
		1 + 4 + 10	249 ± 2	0.12 ± 0.01	0.12 ± 0.04	0.20 ± 0.08	5.82 ± 0.01	5.86 ± 0.01
		4 + 1 + 10	249 ± 3	0.12 ± 0.01	0.08 ± 0.03	0.19 ± 0.06	5.82 ± 0.03	5.80 ± 0.01
	Cefotaxime + morphine + Numeta G13E +	1 + 1 + 1	240 ± 2	0.09 ± 0.03	0.05 ± 0.01	0.03 ± 0.01	5.69 ± 0.02	5.66 ± 0.01
		1 + 2 + 20	272 ± 31	0.20 ± 0.07	0.19 ± 0.04	0.15 ± 0.06	5.81 ± 0.03	5.81 ± 0.03
		9 + 1 + 2	279 ± 2	0.12 ± 0.01	0.06 ± 0.01	0.03 ± 0.00	5.45 ± 0.02	5.44 ± 0.01

^aOne parallel/sample was contaminated and was excluded

^*Values outside the acceptance criteria